Let's check out two exciting biotech stocks that may climb 58% and 200%, according to Wall Street. Image source: Getty Images ...
Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...
2d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNA nanotechnology, ...
China research team at Wuhan University of Science and Technology uses CRISPR to remove HIV DNA from human cells, marking a potential breakthrough in treatment.
Oceanic ecosystems are increasingly threatened by global warming, which causes coral bleaching, species migration and, ...
MarketBeat on MSN
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory. The company ...
Researchers at Texas A&M are pairing a widely used ingredient with advanced medical technology to develop new treatments for ...
Researchers developed a CRISPR-based system that spreads through bacterial populations to disable antibiotic resistance genes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results